Cureety, founded in 2018, is transforming cancer care in Europe by delivering a premier digital health platform designed to enhance patient follow-up and treatment while supporting real-world research on pioneering therapies. This innovative platform serves healthcare facilities, academic research groups, and pharmaceutical companies, situating Cureety at the intersection of Health Care and Health and Wellness.
Headquartered in France, Cureety recently secured a €5.00M Series A investment on 24 January 2022, with backing from key investors including Bpifrance, Crédit Agricole, Credit Mutuel, MBA Mutuelle, and Groupama. These investors recognize Cureety's potential to enhance the delivery and outcomes of cancer care through technological innovation. With this funding, Cureety is well-positioned to further its mission in revolutionizing cancer care.